NCT07503834|RecruitingPhase 1/2DMC
"IL-1β Blockade to Prevent Immunothrombosis in Recipients of a Pancreatic Organ"
ILIPO
Loading search results
Sponsor study identifier
interventional
15
1 country
2
Study Start
October 7, 2026
Actual (reported)Primary Completion
April 7, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
April 7, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
A prospective, open-label, uncontrolled, non-randomized, single-center Phase I/II clinical trial evaluating the safety of Anakinra in the immediate post-transplant period following pancreatic transplantation
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
April 7, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 17, 2026
Actual (reported)March 31, 2026
Actual (reported)October 7, 2026
Actual (reported)April 7, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
April 7, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
evaluate the safety of IL-1β in a pilot study of patients who have undergone a pancreas transplant
Type, severity (CTACAE, and 2012 KDIGO classification for kidney damage) and number (and percentage) of adverse events occurring within the first year following pancreatic transplantation, with a particular focus on severe infections (bacterial, viral, fungal, or parasitic infections that are life-threatening and/or require hospitalization), the occurrence of rejection confirmed by biopsy, and graft survival compared to a historical control cohort (DIVAT Nantes Cohort).
1 year
Assess patient survival one year after transplantation
1 year
Assess pancreatic graft survival one year post-transplant
1 year
Assess pancreatic graft function
1 year
Assess pancreatic graft function
1 year post-transplant
Assess pancreatic graft function
1 year
Safety of Anakinra in the immediate aftermath of pancreatic transplantation
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
PROGRAF 1 mg capsule
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
CAPSULE, HARD
View registry recordFormulated product
Erelzi 25 mg solution for injection in pre-filled syringe.
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INJECTION
View registry recordFormulated product
Kineret 100 mg/0.67 ml solution for injection in pre-filled syringe.
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INJECTION
View registry recordFormulated product
Myfortic 360 mg gastrorezistentné tablety
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
GASTRO-RESISTANT TABLET
View registry recordThe registry names these ingredients. The formulation’s exact chemical form has not been confirmed.
PROGRAF 1 mg capsule
Named ingredient: Tacrolimus
View registry recordErelzi 25 mg solution for injection in pre-filled syringe.
Named ingredient: Etanercept
View registry recordKineret 100 mg/0.67 ml solution for injection in pre-filled syringe.
Named ingredient: Anakinra
View registry recordMyfortic 360 mg gastrorezistentné tablety
Named ingredient: Mycophenolic acid
View registry recordCHU de Nantes - Service ITUN
Nantes, 44000, France
CHU Nantes - Service de réa
Nantes, France
First Submitted
March 17, 2026
First Posted
March 31, 2026
Study Start
October 7, 2026
Actual (reported)Primary Completion
April 7, 2029
Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Heart Failure
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
April 7, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 13, 2026
Record last verified: 2026-10
Study fields come from the primary record; confirmed relationships can use other sources. Selecting a record here changes its provenance and downloads, without replacing the displayed study fields.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: